- Home
- VERU
VERU
Veru Inc.
as 12-17-2024 4:00pm EST
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
| Founded: | 1971 | Country: | United States |
| Employees: | N/A | City: | MIAMI |
| Market Cap: | 107.2M | IPO Year: | 1990 |
| Target Price: | $4.00 | AVG Volume (30 days): | 978.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.28 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $1.92 | Next Earning Date: | 02-06-2025 |
| Revenue: | $16,886,419 | Revenue Growth: | -6.20% |
| Revenue Growth (this year): | -13.71% | Revenue Growth (next year): | -7.30% |
Latest Veru Inc. News
VERU Breaking Stock News: Dive into VERU Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
Simply Wall St.
2 days ago
US Penny Stocks To Consider In December 2024
Simply Wall St.
7 days ago
The past three years for Veru (NASDAQ:VERU) investors has not been profitable
GlobeNewswire
22 days ago
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
GlobeNewswire
a month ago
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
GlobeNewswire
2 months ago
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss
GlobeNewswire
2 months ago
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress
GuruFocus.com
2 months ago
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
Compare VERU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERU Veru Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.